Prime Medicine shares rise 11.62% intraday following announcement of presentation at 44th Annual J.P. Morgan Healthcare Conference.

Prime Medicine (Nasdaq: PRME) surged 11.62% intraday following the announcement that its CEO, Allan Reine, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company highlighted its proprietary Prime Editing platform and diversified pipeline targeting liver, lung, immunology, and oncology, with a focus on curative genetic therapies. The presentation, accessible via live webcast and replay, is expected to enhance investor visibility into its therapeutic development progress and strategic expansion plans. The rally reflects positive market sentiment toward the conference participation, which typically amplifies institutional interest and underscores the company’s long-term innovation potential.